Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07484217 · ClinicalTrials.gov registry record · Phase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
A Phase 3 study of Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms, sponsored by Axsome Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 508
- Enrollment target
- 13
- Study locations
NCT07484217: Recruiting Phase 3 study of Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms, sponsored by Axsome Therapeutics.
NCT07484217 is a Phase 3 study of Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms that is actively recruiting participants, run by Axsome Therapeutics. The registered enrollment target is 508 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower). The trial reports 13 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07484217, a Phase 3 study of Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms, is actively recruiting participants, sponsored by Axsome Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 508 participants
- Enrollment target
- 13
- Study locations
Study Summary
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Solriamfetol 150 MG
Study Locations (13)
California
- Clinical Research Site - Chino
- Clinical Research Site - Redlands
- Clinical Research Site - Walnut Creek
Florida
- Clinical Research Site - Jacksonville
- Clinical Research Site - Miami
New Jersey
- Clinical Research Site - Cherry Hill
- Clinical Research Site - Toms River
New York
- Clinical Research Site - Brooklyn
- Clinical Research Site - The Bronx
Ohio
- Clinical Research Site - Cincinnati
Oregon
- Clinical Research Site - Portland
Tennessee
- Clinical Research Site - Memphis
Texas
- Clinical Research Site - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2026-02-23 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
What NCT07484217 shows while recruiting
NCT07484217 is an interventional study that assigns participants to a tested intervention. The registered 508 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07484217 lists 13 locations in 8 states (California, Florida, New Jersey).
Frequently Asked Questions
What is clinical trial NCT07484217 about?
NCT07484217 is a clinical study titled "Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol". CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptom...
What is the current status of trial NCT07484217?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 508 participants. The study started on 2026-02-23. Estimated completion is 2028-12.
What conditions does trial NCT07484217 study?
This clinical trial studies the following conditions: Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms.
What interventions are being tested in trial NCT07484217?
The interventions under investigation include: Placebo (DRUG), Solriamfetol 150 MG (DRUG).
Who is sponsoring clinical trial NCT07484217?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07484217 being conducted?
This trial has 13 study locations across California, Florida, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07484217's enrollment target sits among peer trials
508 737th of 2000 higher than 1,263 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT04692675 · 508 participants · NA
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- NCT07391657 · 508 participants · Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- NCT06164717 · 507 participants · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI